Shimizu Hideo, Nakagami Hironori, Morishita Ryuichi
Department of Nutritional Sciences for Well-being, Kansai University of Welfare Sciences, Japan/Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Japan.
Clin Calcium. 2014 Jul;24(7):53-62.
Hypertension, osteoporosis and vascular calcification are major diseases in the recent aging society and may share the same backgrounds genetically and environmentally. As treatments to prevent aging-related diseases simultaneously are desirable, we investigate common backgrounds underling these diseases. Renin- angiotensin system, which causes high blood pressure, is found to be involved in bone metabolism. Angiotensin II has been shown to accelerate osteoporosis through RANKL up-regulation in osteoblast. RANKL, in turn, contributes to vascular calcification by regulating bone morphogenetic protein-2 and MGP expression, as well as bone-related proteins. Angiotensin type 1 receptor blockers (ARBs) ameliorate osteoporosis and vascular calcification beyond their blood pressure lowering effects. These pleiotropic effects of antihypertensive drugs such as ARBs might benefit especially hypertensive postmenopausal women.
高血压、骨质疏松症和血管钙化是现代老龄化社会中的主要疾病,它们可能在遗传和环境方面具有相同的背景。由于人们期望有能同时预防与衰老相关疾病的治疗方法,我们对这些疾病的共同背景进行了研究。发现导致高血压的肾素-血管紧张素系统参与骨代谢。血管紧张素II已被证明可通过上调成骨细胞中的核因子κB受体活化因子配体(RANKL)来加速骨质疏松症。反过来,RANKL通过调节骨形态发生蛋白-2和基质Gla蛋白(MGP)的表达以及与骨相关的蛋白质,促进血管钙化。1型血管紧张素受体阻滞剂(ARB)除了具有降压作用外,还能改善骨质疏松症和血管钙化。ARB等降压药物的这些多效性作用可能对尤其是高血压绝经后女性有益。